Investments
54Portfolio Exits
9Funds
1About Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi. The firm invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. The company is based in Cambridge, Massachusetts.
Research containing Sanofi Ventures
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Sanofi Ventures in 1 CB Insights research brief, most recently on Nov 30, 2022.
Latest Sanofi Ventures News
Dec 5, 2023
PARIS--(BUSINESS WIRE)--Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures. This infusion of capital, supported by new investor Bpifrance (through its InnoBio 2 fund), and existing backers Khosla Ventures and Seventure Partners (with Health For Life Capital™), propels Eligo towards becoming a clinical-stage biotech
Sanofi Ventures Investments
54 Investments
Sanofi Ventures has made 54 investments. Their latest investment was in Eligo Bioscience as part of their Series B on December 12, 2023.
Sanofi Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/5/2023 | Series B | Eligo Bioscience | $29.69M | Yes | 1 | |
11/15/2023 | Series A | T-Therapeutics | $59.85M | Yes | 1 | |
10/11/2023 | Series D | MinervaX | $57.27M | No | 1 | |
9/12/2023 | Series B - II | |||||
8/17/2023 | Series B |
Date | 12/5/2023 | 11/15/2023 | 10/11/2023 | 9/12/2023 | 8/17/2023 |
|---|---|---|---|---|---|
Round | Series B | Series A | Series D | Series B - II | Series B |
Company | Eligo Bioscience | T-Therapeutics | MinervaX | ||
Amount | $29.69M | $59.85M | $57.27M | ||
New? | Yes | Yes | No | ||
Co-Investors | |||||
Sources | 1 | 1 | 1 |
Sanofi Ventures Portfolio Exits
9 Portfolio Exits
Sanofi Ventures has 9 portfolio exits. Their latest portfolio exit was Q32 Bio on November 16, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
11/16/2023 | Acq - Pending | 2 | |||
Date | 11/16/2023 | ||||
|---|---|---|---|---|---|
Exit | Acq - Pending | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 2 |
Sanofi Ventures Fund History
1 Fund History
Sanofi Ventures has 1 fund, including Evergreen Venture Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
1/11/2023 | Evergreen Venture Fund | $750M | 1 |
Closing Date | 1/11/2023 |
|---|---|
Fund | Evergreen Venture Fund |
Fund Type | |
Status | |
Amount | $750M |
Sources | 1 |
Sanofi Ventures Team
3 Team Members
Sanofi Ventures has 3 team members, including current Managing Director, Jason P. Hafler.
Name | Work History | Title | Status |
|---|---|---|---|
Jason P. Hafler | Translate Bio, Atlas Venture, and JSB-Partners | Managing Director | Current |
Name | Jason P. Hafler | ||
|---|---|---|---|
Work History | Translate Bio, Atlas Venture, and JSB-Partners | ||
Title | Managing Director | ||
Status | Current |
Loading...